Effects of mTOR inhibitor–related proteinuria on progression of cardiac allograft vasculopathy and outcomes among heart transplant recipients
暂无分享,去创建一个
A. Lerman | S. Kushwaha | J. Stulak | A. Briasoulis | N. Pereira | R. Daly | A. Clavell | B. Edwards | R. Asleh | T. Toya | H. Alnsasra | H. Alnsasra
[1] G. Dellgren,et al. Everolimus Initiation With Early Calcineurin Inhibitor Withdrawal in De Novo Heart Transplant Recipients: Long-term Follow-up From the Randomized SCHEDULE Study , 2020, Transplantation.
[2] Byron H. Smith,et al. Incidence of Malignancies in Patients Treated With Sirolimus Following Heart Transplantation. , 2019, Journal of the American College of Cardiology.
[3] J. Stypmann,et al. Comparing everolimus‐based immunosuppression with reduction or withdrawal of calcineurin inhibitor reduction from 6 months after heart transplantation: The randomized MANDELA study , 2019, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[4] A. Karimpour-Fard,et al. Elevated serum vascular endothelial growth factor and development of cardiac allograft vasculopathy in children. , 2018, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[5] W. Kremers,et al. Long-Term Sirolimus for Primary Immunosuppression in Heart Transplant Recipients. , 2018, Journal of the American College of Cardiology.
[6] A. Yeung,et al. Angiotensin-Converting Enzyme Inhibition Early After Heart Transplantation. , 2017, Journal of the American College of Cardiology.
[7] J. F. Keane,et al. Vascular endothelial growth factor A is associated with the subsequent development of moderate or severe cardiac allograft vasculopathy in pediatric heart transplant recipients. , 2017, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[8] G. Ewald,et al. Everolimus Versus Mycophenolate Mofetil in Heart Transplantation: A Randomized, Multicenter Trial , 2013, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[9] D. Mancini,et al. Randomized Controlled Trial of Sirolimus Conversion in Cardiac Transplant Recipients With Renal Insufficiency , 2012, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[10] Charles M. Miller,et al. An emerging population: kidney transplant candidates who are placed on the waiting list after liver, heart, and lung transplantation. , 2010, American Society of Nephrology. Clinical Journal.
[11] F. Lehner,et al. Biopsy‐Diagnosed Renal Disease in Patients After Transplantation of Other Organs and Tissues , 2010, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[12] M. Bailey,et al. Late Onset Antibody-Mediated Rejection and Endothelial Localization of Vascular Endothelial Growth Factor Are Associated With Development of Cardiac Allograft Vasculopathy , 2008, Transplantation.
[13] W. Kremers,et al. Replacement of Calcineurin-Inhibitors With Sirolimus as Primary Immunosuppression in Stable Cardiac Transplant Recipients , 2007, Transplantation.
[14] E. Letavernier,et al. High sirolimus levels may induce focal segmental glomerulosclerosis de novo. , 2007, Clinical journal of the American Society of Nephrology : CJASN.
[15] P. Beaune,et al. Role of P-glycoprotein in cyclosporine cytotoxicity in the cyclosporine-sirolimus interaction. , 2006, Kidney international.
[16] J. Kirklin,et al. Increasing referral for renal transplant evaluation in recipients of nonrenal solid-organ transplants: a single-center experience. , 2006, Clinical journal of the American Society of Nephrology : CJASN.
[17] G. Ewald,et al. Tacrolimus with Mycophenolate Mofetil (MMF) or Sirolimus vs. Cyclosporine with MMF in Cardiac Transplant Patients: 1‐Year Report , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[18] J. Wetzels,et al. Sirolimus‐Associated Heavy Proteinuria in a Renal Transplant Recipient: Evidence for a Tubular Mechanism , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[19] A. Pariente,et al. Proteinuria Following a Switch from Calcineurin Inhibitors to Sirolimus , 2005, Transplantation.
[20] H. Izzedine,et al. Post-transplantation proteinuria and sirolimus. , 2005, The New England journal of medicine.
[21] P. Armstrong,et al. Renal Insufficiency and Heart Failure: Prognostic and Therapeutic Implications From a Prospective Cohort Study , 2004, Circulation.
[22] R. Wolfe,et al. Chronic renal failure after transplantation of a nonrenal organ. , 2003, The New England journal of medicine.
[23] E. Tuzcu,et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. , 2003, The New England journal of medicine.
[24] P. Ganz,et al. EXPRESSION PATTERNS OF VASCULAR ENDOTHELIAL GROWTH FACTOR IN HUMAN CARDIAC ALLOGRAFTS: ASSOCIATION WITH REJECTION , 2003, Transplantation.
[25] M. Arias,et al. The risk of cardiovascular disease associated with proteinuria in renal transplant patients. , 2002, Transplantation.
[26] C. Mavroudis,et al. Serum vascular endothelial growth factor as a surveillance marker for cellular rejection in pediatric cardiac transplantation. , 2002, Transplantation.
[27] M. Sabbatini,et al. Acute effects of rapamycin on glomerular dynamics: a micropuncture study in the rat. , 2000, Transplantation.
[28] F. Waagstein,et al. Predictors and evolution of renal function during 9 years following heart transplantation. , 2000, Journal of the American Society of Nephrology : JASN.
[29] Y. Shyr,et al. Long-term renal function in heart transplant recipients receiving cyclosporine therapy. , 1997, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[30] W. Bennett,et al. Synergistic effects of cyclosporine and rapamycin in a chronic nephrotoxicity model. , 1996, Transplantation.
[31] N. Perico,et al. Nature and extent of glomerular injury induced by cyclosporine in heart transplant patients. , 1991, Kidney international.